Annovis Bio, Inc. — Form 8-K
Filed August 14, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
Annovis completed enrollment of its pivotal Phase 3 Alzheimer's disease trial with 850 patients (exceeding the 760-patient target), with topline symptomatic data expected in Q1 2027 and disease-modifying data one year later. Cash and equivalents declined from $19.5M (Dec 31, 2025) to $18.7M (Jun 30, 2026); Q2 2026 R&D expenses were $12.0M vs. $5.2M year-over-year. The warrant liability surged from $595K to $19.9M, and stockholders' equity swung from +$16.9M to negative $4.3M due to share dilution (42.6M shares outstanding vs. 27.2M at year-end 2025) and accumulated losses of $196.1M.
Why this rating
Phase 3 enrollment milestone is clinically significant with 2027 data approaching, but company's $18.7M cash (52% of market cap) with $14.4M quarterly burn and negative equity poses material near-term funding risk despite trial progress.
See more from August 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.